Department of Medicine
Co-Director,
Thomas A. Hensing, MDThoracic Oncology Program

Education

  • Undergraduate:  BS, Biology, Loyola College, Baltimore, MD
  • Medical School:  MD, University of Maryland School of Medicine, Baltimore, MD
  • Internship:  Medicine, University of North Carolina, Chapel Hill, NC
  • Residency:  Hematology-Oncology, University of North Carolina, Chapel Hill, NC

Honors and Awards 

  • Fellow of the Year, Department of Internal Medicine, UNC Chapel Hill (1998)
  • Robert L. Nye Award, Department of Internal Medicine, UNC Chapel Hill (1997)

Professional Memberships/Affiliations/Activities:  

  • (1997-present)   American Association for Cancer Research
  • (1999-present)   Cancer and Leukemia Group B
  • (2000-present)   American Society of Clinical Oncology
  • (2003-present)   Eastern Cooperative Oncology Group
  • (2003-present)   International Association for the Study of Lung Cancer
  • (2003-present)   Illinois Medical Oncology Society
  • (2003-present)   Thoracic Committee, Eastern Cooperative Oncology Group
  • (2003-present)   Clinical Protocol Scientific Review Committee, NUMS  
  • (2003-present)   NorthShore University HealthSystem Cancer Committee
  • (2003-present)   Chair, NorthShore University HealthSystem Cancer Committee Performance Improvement Subcommittee
  • (2005-present)   American College of Chest Physicians

Scholarly Work 

Publications in Peer-Review Journals: 

  1. Ewend, MG, Carey, LA, Morris, DE, Harvey, RD, Hensing, TABrain Metastases. Current Treatment Options in Oncology,2:537-547, 2001.
  2. Gillenwater HH, Stinchcombe TE, Qaqish BF, Tynan M, Hensing TA, Socinski MA. A phase II trial of weekly paclitaxel and gemcitabine infused at a constant rate in patients with advanced non-small cell lung cancer.  Lung Cancer, In Press, 2005. 
  3. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA.  Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.  Journal of Clinical Oncology, 22:4785-4793, 2004.
  4. Hensing, TA.  Chemoradiotherapy for stage IIIA and IIIB non-small cell lung cancer.  Updates, 1:1-13, 2000.
  5. Hensing, TA.  Clinical evaluation and staging of patients who have lung cancer.  Hematology/Oncology Clinics of North America. In press, 2005.
  6. Hensing TA, Masters GA.  A patient with non-small-cell lung cancer treated with docetaxel/carboplatin.  Case Studies in Lung Cancer 2(No. 1):2-7. 2003.
  7. Hensing TA, Peterman AH, Schell MJ, Socinski, MA.  The Impact of Age on Toxicity, Response Rate, Quality-of-life and Survival in Patients with Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Treated with Carboplatin and Paclitaxel.  Cancer, 98(4):779-788, 2003.
  8. Hensing TA, Schell, MJ, Lee JH, Socinski MA.  Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer.  Lung Cancer. 42(2):253-259, 2005.  
  9. Hensing TA, Socinski MA.  Treatment of advanced non-small cell lung cancer in the elderly;  The role of third-generation platinum-based combination chemotherapy.  The American Journal of Oncology Review, 3(3):146-151, 2004.
  10. Hensing TA, Socinski MA.  Chemotherapy for advanced stage non-small cell lung cancer; Impact on the elderly and poor performance status populations.  Updates, 4(No. 1):1-9, 2003.
  11. Hensing TA, Socinski MA. Combined- modality therapy in the non-surgical management of unresectable stage III non-small cell lung cancer.  Current Opinion in Pulmonary Medicine, 5(4):194-200, 1999.
  12. Hensing, TA, Socinski, MA.  The role of induction therapy in the management of resectable non-small cell cancer.  Cancer Control. 7(1):45-55, 2000.
  13. Kwock L, Smith JK, Castillo M, Ewend MG, Cush S, Hensing TA, Varia M,Morris D, Bouldin TW.  Clinical Applications of Proton MR Spectroscopy in Oncology.  Technology in Cancer Research & Treatment, 1(1):1-10, 2002.
  14. Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, Ollila DW.  Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness = 1.0 mm).  Annals of Surgical Oncology, 11(10)< /STRONG > :900-6, 2004.
  15. Socinski MA, Baggstrom MQ, Hensing TA.   Duration of therapy in advanced, metastatic non-small-cell lung cancer.  Clinical Advances in Hematology & Oncology, 1(No. 1): 33-38, 2003.
  16. Socinski MA, Morris DE, Halle J, Moore D, Hensing TA, Limentani S, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG.  Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA/B non-small cell lung cancer:  A dose escalation phase I trial.  Journal of Clinical Oncology, 22:4341-4350, 2004.
  17. Thomas NE, Ollila DW, Hensing TA.  Advances and challenges in melanoma.  Skin & Aging, 47-57, 2003.

Book Chapters:

  1. Roberts HR, Hensing TA.  Blood components and concentrates in the management of bleeding after cardiopulmonary bypass.  In Pifarre R (ed): Management of Bleeding in Cardiovascular Surgery.  Philadelphia, Hanley and Belfus; 1999: 307-322.
  2. Hensing, TA, Halle, JS, Socinski, MA.  Chemoradiotherapy for IIIA and IIIB non-small cell lung cancer.  In Detterbeck, FC (ed): Diagnosis and Treatment of Lung Cancer.  New York, W.B. Saunders Company; 2000: 291-303.
× Alternate Text